Spectrum Pharmaceuticals Inc. (SPPI)

9.57
NASDAQ : Health Technology
Prev Close 10.21
Day Low/High 9.52 / 10.26
52 Wk Low/High 6.22 / 25.29
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 104.06M
Market Cap 1.06B
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of SPPI March 15th Options Trading

First Week Of SPPI March 15th Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the March 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new March 15th contracts and identified the following call contract of particular interest.

Spectrum Pharmaceuticals Announces The Completion Of The Sale Of Its Marketed Portfolio

Spectrum Pharmaceuticals Announces The Completion Of The Sale Of Its Marketed Portfolio

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.

Spectrum Pharmaceuticals Reports Fourth Quarter 2018 And Full Year 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Fourth Quarter 2018 And Full Year 2018 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and year ended December 31, 2018.

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results Conference Call

Spectrum Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results Conference Call

Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for the...

Spectrum Pharmaceuticals To Present Corporate Update At The Guggenheim Healthcare Talks Idea Forum On February 14

Spectrum Pharmaceuticals To Present Corporate Update At The Guggenheim Healthcare Talks Idea Forum On February 14

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York.

Spectrum Pharma Sells Marketed Portfolio in a Deal That Could Reach $300 Million

Spectrum Pharma Sells Marketed Portfolio in a Deal That Could Reach $300 Million

Spectrum sells its marketed portfolio of seven FDA-approved products to Acrotech Bio for $160 million up front with a potential for $140 million more in regulatory and sales-based milestones.

Spectrum Pharmaceuticals Sells Marketed Portfolio To Acrotech Biopharma L.L.C. To Focus On New And Innovative Therapies For Cancer Patients

Spectrum Pharmaceuticals Sells Marketed Portfolio To Acrotech Biopharma L.L.C. To Focus On New And Innovative Therapies For Cancer Patients

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) announced today that it has entered into a definitive agreement to sell its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.

Spectrum Pharmaceuticals Announces Full Enrollment Of The Poziotinib EGFR Cohort For Previously Treated Non-Small Cell Lung Cancer Patients With Exon 20 Insertion Mutations

Spectrum Pharmaceuticals Announces Full Enrollment Of The Poziotinib EGFR Cohort For Previously Treated Non-Small Cell Lung Cancer Patients With Exon 20 Insertion Mutations

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced full enrollment of cohort 1 (N=87) for previously...

Spectrum Pharmaceuticals Announces Submission Of Biologics License Application To The FDA For ROLONTIS® (eflapegrastim) As A Treatment For Chemotherapy-Induced Neutropenia

Spectrum Pharmaceuticals Announces Submission Of Biologics License Application To The FDA For ROLONTIS® (eflapegrastim) As A Treatment For Chemotherapy-Induced Neutropenia

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that the company submitted a Biologics License...

Spectrum Pharmaceuticals Provides Poziotinib Update

Spectrum Pharmaceuticals Provides Poziotinib Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), today announced that based on a subset of data from MD Anderson's ongoing Phase 2 study, the U.

Spectrum Pharmaceuticals Announces Results From The RECOVER Phase 3 Study Of ROLONTIS® (eflapegrastim) At The 2018 SABCS Annual Meeting

Spectrum Pharmaceuticals Announces Results From The RECOVER Phase 3 Study Of ROLONTIS® (eflapegrastim) At The 2018 SABCS Annual Meeting

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that data from the Phase 3 RECOVER clinical study...

Spectrum Pharmaceuticals Announces Positive Results From Phase 2 Trial Evaluating Use Of Oral Leucovorin To Potentially Mitigate Mucositis In Patients Treated With FOLOTYN® (pralatrexate)

Spectrum Pharmaceuticals Announces Positive Results From Phase 2 Trial Evaluating Use Of Oral Leucovorin To Potentially Mitigate Mucositis In Patients Treated With FOLOTYN® (pralatrexate)

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced results from a prospective Phase 2 single-arm,...

Spectrum Pharmaceuticals Highlights Three Posters At The 60th Annual Meeting Of The American Society Of Hematology

Spectrum Pharmaceuticals Highlights Three Posters At The 60th Annual Meeting Of The American Society Of Hematology

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced presentations of clinical and scientific data related to...

Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca To Its Board Of Directors

Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca To Its Board Of Directors

Spectrum Pharmaceuticals Inc., (NASDAQ: SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca, MD, FACP to its...

Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update And Financial Results

Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update And Financial Results

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended...

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2018 London Healthcare Conference On November 14

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies 2018 London Healthcare Conference On November 14

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and...

Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management...

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Running Hot: Cramer's 'Mad Money' Recap (Friday 10/5/18)

Jim Cramer says it'll be hard for stocks to stabilize until the Fed's stance softens. He's got your game plan for next week.

Camping World, American Electric Power: 'Mad Money' Lightning Round

Camping World, American Electric Power: 'Mad Money' Lightning Round

Jim Cramer takes a look at Camping World, American Electric Power, Avangrid, Dominion Energy, Thor Industries, Spectrum Pharmaceuticals and more.

Spectrum Pharmaceuticals Receives FDA Approval Of KHAPZORY™ (levoleucovorin) For Injection

Spectrum Pharmaceuticals Receives FDA Approval Of KHAPZORY™ (levoleucovorin) For Injection

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the U.

Spectrum Pharmaceuticals Announces Dr. Francois Lebel As Chief Medical Officer

Spectrum Pharmaceuticals Announces Dr. Francois Lebel As Chief Medical Officer

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Francois Lebel, M.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: MTR Downgrades: ELLI, GRPN, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Spectrum Pharmaceuticals To Present Corporate Update At The 2018 Cantor Global Healthcare Conference On October 2

Spectrum Pharmaceuticals To Present Corporate Update At The 2018 Cantor Global Healthcare Conference On October 2

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and...

Spectrum Pharmaceuticals Announces Release Of Updated Poziotinib Data From MD Anderson Phase 2 Study In Non-Small Cell Lung Cancer Patients

Spectrum Pharmaceuticals Announces Release Of Updated Poziotinib Data From MD Anderson Phase 2 Study In Non-Small Cell Lung Cancer Patients

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced preliminary poziotinib data from the University of...

Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy And Doses First Patient

Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy And Doses First Patient

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has initiated two new cohorts for...

Spectrum Pharmaceuticals Announces Release Of Poziotinib Abstract As Part Of The IASLC 19th World Conference On Lung Cancer

Spectrum Pharmaceuticals Announces Release Of Poziotinib Abstract As Part Of The IASLC 19th World Conference On Lung Cancer

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced new interim poziotinib data from the MD Anderson...

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals To Present At Two Upcoming Investor Conferences In September

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, DSS, ENDP, ICUI, PIH, SPB, SPPI, WAAS, YRD Downgrades: BMA, BRT, ELSE, FRBK, HAE, HSKA, JD, MATW, TCMD, TSG Initiations: ALT, TRTX Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: D (Sell)